Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246491 · ClinicalTrials.gov registry record · NA
Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia
A NA study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02246491: Clinical Trial NA study, sponsored by Johns Hopkins University.
NCT02246491 is a NA study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02246491, a NA study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
This research is being done to better understand the causes of the disease Ataxia-Telangiectasia and, in the longer-term, develop new therapies for the disease using stem cells. Induced pluripotent stem cells (iPSC) are a type of cells that can be made in the laboratory from cells in your body, such as blood cells or skin cells (fibroblasts). These stem cells can then be used for research purposes. For example, stem cells can be used to investigate how the mutation in ATM causes the actual symptoms of Ataxia-Telangiectasia. In addition, the stem cells can be used to screen for drugs that could be helpful to treat the disease or to develop new laboratory techniques to correct the mutation that causes Ataxia-Telangiectasia. where the mutation that causes the disease is corrected by the investigators. The stem cells generated in this study will not be used directly for patient therapy and therefore this research does not have a direct benefit to you. However, it will help advance our understanding of the disease and develop future therapies. Patients who enroll in this study will get all of the standard therapy they would get for their tumor whether or not they participate in this study. There is no extra or different therapy given. The study involves a one-time procedure (either blood collection or skin biopsy).
Interventions
- OTHER A-T iPS cell line
- OTHER Carrier patients iPS cell line
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-02-03 |
| Est. Completion | 2018-07-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02246491
The ClinicalTrials.gov registry entry for NCT02246491 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which A-T iPS cell line is the first listed.
NCT02246491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02246491 about?
NCT02246491 is a clinical study titled "Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia". This research is being done to better understand the causes of the disease Ataxia-Telangiectasia and, in the longer-term, develop new therapies for the disease using stem cells. Induced pluripotent stem cells (iPSC) are a type of cells that can be made in the laboratory from cells in your body, suc...
What is the current status of trial NCT02246491?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2015-02-03. Estimated completion is 2018-07-05.
What interventions are being tested in trial NCT02246491?
The interventions under investigation include: A-T iPS cell line (OTHER), Carrier patients iPS cell line (OTHER).
Who is sponsoring clinical trial NCT02246491?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.